$62.58 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter

Analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to post $62.58 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $67.73 million and the lowest is $56.70 million. Amphastar Pharmaceuticals posted sales of $63.54 million during the same quarter last year, which suggests a negative year over year growth rate of 1.5%. The company is expected to issue its next quarterly earnings results on Monday, March 12th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $62.58 million for the current year, with estimates ranging from $234.00 million to $247.51 million. For the next fiscal year, analysts expect that the firm will report sales of $312.39 million per share, with estimates ranging from $299.80 million to $325.30 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The business’s revenue was down 9.8% compared to the same quarter last year.

A number of equities analysts recently issued reports on AMPH shares. BMO Capital Markets raised their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Raymond James Financial lowered Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target on the stock. in a report on Thursday, November 9th. Needham & Company LLC lifted their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Finally, Jefferies Group set a $19.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $19.50.

Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at $18.28 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a twelve month low of $12.05 and a twelve month high of $19.95. The stock has a market capitalization of $862.97, a PE ratio of 125.13, a P/E/G ratio of 1.32 and a beta of 1.69.

In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the business’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $18.73, for a total value of $147,255.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 3,026 shares of the business’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $18.56, for a total value of $56,162.56. The disclosure for this sale can be found here. Insiders have sold a total of 92,060 shares of company stock worth $1,716,956 in the last three months. Corporate insiders own 11.10% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at $400,000. Argent Capital Management LLC raised its holdings in Amphastar Pharmaceuticals by 102.6% in the 3rd quarter. Argent Capital Management LLC now owns 121,275 shares of the company’s stock valued at $2,167,000 after acquiring an additional 61,425 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in Amphastar Pharmaceuticals by 1.8% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 283,200 shares of the company’s stock valued at $5,060,000 after acquiring an additional 5,000 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Amphastar Pharmaceuticals by 17.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock valued at $27,844,000 after acquiring an additional 226,271 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in Amphastar Pharmaceuticals by 11.6% in the 3rd quarter. Nordea Investment Management AB now owns 129,046 shares of the company’s stock valued at $2,306,000 after acquiring an additional 13,439 shares during the last quarter. Institutional investors own 44.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: “$62.58 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/05/62-58-million-in-sales-expected-for-amphastar-pharmaceuticals-inc-amph-this-quarter.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply